196 related articles for article (PubMed ID: 33124053)
21. Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity.
Li F; Fridley BL; Matimba A; Kalari KR; Pelleymounter L; Moon I; Ji Y; Jenkins GD; Batzler A; Wang L; Weinshilboum RM
Drug Metab Dispos; 2010 Dec; 38(12):2329-38. PubMed ID: 20855458
[TBL] [Abstract][Full Text] [Related]
22. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
Lancaster DL; Patel N; Lennard L; Lilleyman JS
Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
24. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard L; Lilleyman JS
J Clin Oncol; 1989 Dec; 7(12):1816-23. PubMed ID: 2585022
[TBL] [Abstract][Full Text] [Related]
25. Two-stage replication of previous genome-wide association studies of AS3MT-CNNM2-NT5C2 gene cluster region in a large schizophrenia case-control sample from Han Chinese population.
Guan F; Zhang T; Li L; Fu D; Lin H; Chen G; Chen T
Schizophr Res; 2016 Oct; 176(2-3):125-130. PubMed ID: 27401531
[TBL] [Abstract][Full Text] [Related]
26. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia.
Innocenti F; Danesi R; Favre C; Nardi M; Menconi MC; Di Paolo A; Bocci G; Fogli S; Barbara C; Barachini S; Casazza G; Macchia P; Del Tacca M
Ther Drug Monit; 2000 Aug; 22(4):375-82. PubMed ID: 10942174
[TBL] [Abstract][Full Text] [Related]
27. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
28. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
29. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
30. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
[TBL] [Abstract][Full Text] [Related]
31. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits].
Fakhoury M; de Beaumais T; Médard Y; Jacqz-Aigrain E;
Therapie; 2010; 65(3):187-93. PubMed ID: 20699069
[TBL] [Abstract][Full Text] [Related]
33. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
Lennard L; Davies HA; Lilleyman JS
Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412
[TBL] [Abstract][Full Text] [Related]
34. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
[TBL] [Abstract][Full Text] [Related]
35. [NT5C2 expression in children with acute leukemia and its clinical significance].
Wang Y; An X; Liu J; Zhang N; Liu Z; Liang S; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):748-53. PubMed ID: 26462774
[TBL] [Abstract][Full Text] [Related]
36. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
Meyer JA; Carroll WL; Bhatla T
Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
[No Abstract] [Full Text] [Related]
37. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
38. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
Hnízda A; Fábry M; Moriyama T; Pachl P; Kugler M; Brinsa V; Ascher DB; Carroll WL; Novák P; Žaliová M; Trka J; Řezáčová P; Yang JJ; Veverka V
Leukemia; 2018 Jun; 32(6):1393-1403. PubMed ID: 29535428
[TBL] [Abstract][Full Text] [Related]
39. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
40. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]